• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Global trends in diabetic eye disease research from 2012 to 2021

    2024-01-24 09:14:44YuanYuanShangliJiYaliSongZhaodiCheLuXiaoShiboTangJiaXiao

    Yuan Yuan ,Shangli Ji ,Yali Song ,Zhaodi Che ,Lu Xiao ,Shibo Tang,,Jia Xiao,,

    Abstract Diabetic eye disease refers to a group of eye complications that occur in diabetic patients and include diabetic retinopathy,diabetic macular edema,diabetic cataracts,and diabetic glaucoma.However,the global epidemiology of these conditions has not been well characterized.In this study,we collected information on diabetic eye disease-related research grants from seven representative countries––the United States,China,Japan,the United Kingdom,Spain,Germany,and France––by searching for all global diabetic eye disease journal articles in the Web of Science and PubMed databases,all global registered clinical trials in the ClinicalTrials database,and new drugs approved by the United States,China,Japan,and EU agencies from 2012 to 2021.During this time period,diabetic retinopathy accounted for the vast majority (89.53%) of the 2288 government research grants that were funded to investigate diabetic eye disease,followed by diabetic macular edema (9.27%).The United States granted the most research funding for diabetic eye disease out of the seven countries assessed.The research objectives of grants focusing on diabetic retinopathy and diabetic macular edema differed by country.Additionally,the United States was dominant in terms of research output,publishing 17.53% of global papers about diabetic eye disease and receiving 22.58% of total citations.The United States and the United Kingdom led international collaborations in research into diabetic eye disease.Of the 415 clinical trials that we identified,diabetic macular edema was the major disease that was targeted for drug development (58.19%).Approximately half of the trials(49.13%) pertained to angiogenesis.However,few drugs were approved for ophthalmic (40 out of 1830;2.19%) and diabetic eye disease (3 out of 1830;0.02%) applications.Our findings show that basic and translational research related to diabetic eye disease in the past decade has not been highly active,and has yielded few new treatment methods and newly approved drugs.

    Key Words:clinical trials;diabetic cataracts;diabetic eye disease;diabetic glaucoma;diabetic macular edema;diabetic retinopathy;drug development;global research;publication;research grant

    Introduction

    According to estimates from the International Diabetes Federation in 2021,approximately 537 million adults between the ages of 20 and 79 years worldwide have been diagnosed with diabetes mellitus.This number is expected to increase to 643 million by 2030 and 783 million by 2045 (Sun et al.,2022).Diabetic eye disease (DED) refers a group of eye complications that affect patients with diabetes (Hanineva et al.,2022;So et al.,2022).These mainly include diabetic retinopathy(DR),diabetic macular edema (DME),diabetic cataracts(DC),and diabetic glaucoma (DG),as defined by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.In 2020,an estimated 103.12 million adults worldwide had DR,representing 22.27% of all adults with diabetes (Teo et al.,2021).Importantly,DR was the only major cause of blindness with a global increase in prevalence from 1990 to 2020 (an increase of 14.9% per 1000 persons),compared with other major eye diseases such as undercorrected refractive error,cataract,age-related macular degeneration,and glaucoma (GBD 2019 Blindness and Vision Impairment Collaborators,2021).The prevalence of DR varies across different regions of the world,with the highest rates in Africa (35.90%) and North America and the Caribbean(33.30%),while the rates are lower in South and Central America (13.37%) and Southeast Asia (16.99%) (Teo et al.,2021).DME can occur at any stage of DR and is characterized by an accumulation of excess fluid in the retinal macular area(Varma et al.,2014).It is the leading cause of vision loss in patients with type 2 diabetes (Romero-Aroca,2011).In the United States,DME affects more than 3.8% of adults aged 40 and above with diabetes,based on 2008 data (Varma et al.,2014;Lundeen et al.,2022).Persistently high blood glucose levels in diabetic patients can cause structural changes to the lens of the eye,accelerating the development of cataracts,also known as diabetic cataracts.Patients with diabetes are up to five times more likely to develop cataracts than individuals without diabetes,particularly at an earlier age (Saxena et al.,2004).Data on the prevalence of DC in the general and diabetic populations are limited.In the United Kingdom,the incidence of cataracts was 20.4 per 1000 person-years in patients with diabetes and 10.8 per 1000 person-years in the general population in 2015 (Becker et al.,2018).Diabetes can cause an obstruction in aqueous outflow and elevate intraocular pressure,which can eventually lead to primary open-angle glaucoma.When patients with diabetes also have blood circulation disorders,this can result in decreased blood flow to the eyes,causing optic nerve damage in glaucoma and normal tension glaucoma.Hyperglycemia can also cause swelling in the lens that can increase intraocular pressure and cause secondary angle-closure glaucoma.The most severe form of glaucoma caused by DR is neovascular glaucoma.Patients with diabetes are twice as likely to develop glaucoma,especially open-angle glaucoma,compared with non-diabetic individuals (Li et al.,2021).The prevalence of glaucoma in patients with diabetes ranges from 4.96% to 14.6%.However,the association between diabetes and DG is significantly influenced by geographic distribution and other factors such as race,age,and sex (Zheng et al.,2010;Zhao and Chen,2017).

    Overall,therapeutic options for DED are limited.Managing blood glucose levels and diabetic progression are crucial at all stages of DED (Stitt et al.,2016).Vascular endothelial growth factor (VEGF) inhibitors,including faricimab-svoa,ranibizumab,aflibercept,and bevacizumab,can help inhibit the growth of new blood vessels and decrease fluid buildup in the context of advanced DR and DME.Photocoagulation (or panretinal photocoagulation) can also be used in conjunction with VEGF inhibitors (Wong et al.,2018).Nevertheless,future retinal damage and vision loss are still possible despite drug or laser therapy slowing or halting the progress of DR/DME because diabetes is a chronic disease.Most types of cataracts,including DC,are preferentially treated with phacoemulsification.However,patients with diabetes have been reported to experience a higher rate of complications(e.g.,poorer vision outcomes) after phacoemulsification cataract surgery than non-diabetic (Pollreisz and Schmidt-Erfurth,2010).For patients with diabetes and primary openangle glaucoma,intraocular pressure (IOP)-lowering drugs(e.g.,prostaglandin analogs),laser,and surgery can be used,as for non-diabetic patients (Tang et al.,2023b).Owing to the rapidly increasing global prevalence of diabetes,a higher DED disease burden is expected in the coming decades.Effective,novel Food and Drug Administration (FDA)-approved drugs and therapies are urgently needed for the management of patients with DED.Developing new medications/treatments depends heavily on rigorous basic and clinical research designed to identify novel disease mechanisms and treatment targets,as well as to generate data on the efficacy and safety of new therapies.Thus,comprehensively analyzing global trends in basic and clinical research into DED is essential to devise evidence-based strategies for future research and therapy development.In this study,we analyzed trends(research grants,publications (from the Web of Science and PubMed databases),clinical trials,and newly approved drugs)in DED research from 2012 to 2021 at a global level.

    Methods

    Data collection

    We collected data on the number of funded projects and total funding amounts for DED-related projects from online information systems: The United States (National Institutes of Health,the USA-NIH): https://reporter.nih.gov/,China(National Natural Science Foundation of China,NSFC): https://kd.nsfc.gov.cn/fundingProjectInit,Japan (Grants-in-Aid for Scientific Research,KAKENHI): https://kaken.nii.ac.jp/,the United Kingdom (Research Councils UK,RCUK): https://gtr.ukri.org/,Spain (El Instituto de Salud Carlos III,ISCIII):https://portalfis.isciii.es/es/Paginas/inicio.aspx,Germany(German Research Foundation,DFG): https://gepris.dfg.de/gepris/OCTOPUS?language=en,and France (French National Research Agency,ANR): https://anr.fr/en/funded-projectsand-impact/funded-projects/.We searched project titles using the keywords “diabetic retinopathy,” “diabetic macular edema,” “diabetic cataracts,” and “diabetic glaucoma”(accessed December 13–15,2022).To assess DED-related journal publications,we searched the Web of Science Core Collection (https://apps.webofknowledge.com/) using the same keywords for the time period spanning 2012–2021(accessed December 15,2022).In addition,we downloaded papers related to DED from the PubMed-MeSH database(https://www.ncbi.nlm.nih.gov/mesh) using the same keywords (accessed December 17,2022).We eliminated duplicate papers and re-retrieved the remaining papers from the Web of Science database.For clinical trial information,we searched the ClinicalTrials website (https://clinicaltrials.gov/)using the keywords “diabetic retinopathy,” “diabetic macular edema,” “diabetic cataracts,” and “diabetic glaucoma” in the“condition or disease” tab (accessed December 17,2022).We collected newly approved drug information from the Food and Drug Administration (FDA) for the United States (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm),the National Medical Products Administration (NMPA) for China (https://www.cde.org.cn/hymlj/index), the Pharmaceuticals and Medical Devices Agency (PMDA) for Japan (https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html), and the European Medicines Agency(EMA) for the European Union (https://www.ema.europa.eu/en/medicines/download-medicine-data#european-publicassessment-reports-(epar)-section) (accessed December 22,2022). We included only new medicinal products and orphan medicinal products, and excluded biosimilar and generic drug information. The authors YY and YS independently analyzed all information on grants, journal papers, clinical trials, and new drugs. Their analyses were later verified by the authors SJ and JX.

    Disease and research coding

    All research grants, journal papers, and clinical trials were manually assigned a disease code (DR, DME, DC, or DG). If a grant, paper, or trial described two diseases, we labeled it with two codes and counted it as 0.5 for each disease in the statistical analysis. We also manually assigned a research code to grants and journal papers to indicate whether they involved basic research (mechanistic study, therapeutic study, novel animal model study, and bioengineering study)or clinical research (epidemiological study, diagnostic study,observational study, or interventional study). If a grant or paper involved both types of research, we assigned it both codes and counted it as 0.5 for each type of study in the statistical analysis.

    Calculation of citations per article, relative citation impact,and closeness centrality of journal papers

    The frequency of citations per article is a relative index that can eliminate differences in country sizes and can better reflect the quality or impact of scientific research. The formula used to calculate this value is as follows: the cited frequency of papers in a country (or a research direction) = the cited frequency of papers in a country (or a research direction)/the number of papers in a country (or a research direction).

    Relative citation impact (RCI) refers to the ratio of the cited frequency of papers published by the country to the cited frequency of papers published by the world (country) (Grover et al., 2021), and it is used to measure the quality or impact of a country in a specified field. The formula used to calculate this value is as follows:

    where Cijrefers to the citation frequency of papers of country i in the discipline field j; Pijrefers to the number of papers of country i in the discipline field j; WCjrefers to the citation frequency of the world’s papers in the discipline field j; and WPjrepresents the number of papers in the world in the subject area j. If the RCI index value is greater than 1, this indicates that the quality or impact of papers in a given field from that country is higher than the average quality or impact of papers in that field from around the world. When the RCI is equal to 1, this means that the quality or impact of papers from that country in that field is equivalent to that of papers from around the world in that same field. Conversely,if the RCI value is less than 1, this indicates that the quality or impact of papers from that country in that field is lower than the average quality or impact of papers from around the world in that same field.

    Closeness centrality describes the control power and influence of nodes in a network (Diallo et al., 2016). The closeness centrality of a node measures its average farness (inverse distance) to all other nodes. Nodes with a high closeness score have a short distance to all other nodes. The “absolute overall centrality” of a point is the sum of the shortcut distances between the point and all other points in the graph, and is expressed as:

    where dijis the shortcut distance between point i and point j, and n is the total number of network nodes. To eliminate the impact of network size on the overall centrality value of points and enhance the comparability of the overall centrality value of network points of different sizes, we introduced the concept of “relative overall centrality.” Because the absolute overall centrality of the core points of the “star” network can reach the minimal valuen–1, the “absolute overall centrality”can be divided by the minimal overall centrality to obtain the“relative overall centrality” (standardization of the overall centrality), which is expressed as:

    wheredijis the shortcut distance between pointiand pointj, andnis the total number of network nodes. The overall centrality value in this study defaults to “relative overall centrality.”

    Statistical analysis

    Only descriptive analyses were conducted in this study.

    Results

    DR accounts for the vast majority of global DED research grants

    From 2012 to 2021, a total of 2288 research grants for DED were awarded by the governments of the seven representative countries (the United States, China, Japan, the United Kingdom, Spain, Germany, and France). DR accounted for the vast majority of global DED grants (2048.5 out of 2288;89.53%), followed by DME (212 out of 2288; 9.27%). DC- and DG-related grants accounted for only very small percentages of overall DED grants (0.9 out of 100 (0.90%) and 0.31 out of 100 (0.31%), respectively). The number and amount of global DED research funds remained relatively stable in this period,at 203 to 245 grants per year and 87.70 to 103.35 million USD per year. The USA-NIH approved 1748 DED grants with a total value of 901.86 million USD, which exceeded the sum of other countries: China approved 264 grants worth 16.07 million USD, Japan approved 161 grants worth 6.34 million USD, the United Kingdom approved 45 grants worth 31.19 million USD,Spain approved 34 grants worth 4.09 million USD, Germany

    approved 26 grants,and France approved eight grants worth 4.18 million USD.This indicated that the United States made the largest investment in this research field during this time period.Only the United States and China funded DC-related grants (12.5 and 8,respectively),and only the United States funded DG-related grants (seven) (Figure 1).

    Figure 1 |Proportions of research grants focusing on the four types of diabetic eye disease (DED)diseases,namely diabetic retinopathy (DR),diabetic macular edema (DME),diabetic cataracts (DC),and diabetic glaucoma (DG),funded by the governments of global representative countries,and trends in funding,from 2012 to 2021.

    The research objectives of DR and DME grants vary by country

    Next,we analyzed the research objectives of all DR-and DMErelated grants.DC-and DG-related grants were not included because there were too few.For DR-related grants,the United States,China,and Japan approved more basic studies than clinical studies,while in European countries (the United Kingdom,Germany,Spain,and France),the numbers of basic and clinical studies were similar (49vs.51;Figure 2A).In the United States,the NIH approved 786 mechanistic studies of DR from 2012 to 2021,followed by 325.5 studies of DR diagnosis and 179 DR clinical observational studies.In China,the NSFC encourages basic/mechanistic studies instead of clinical studies,and thus most of the approved DR grants were for studies that proposed to address molecular mechanisms(64.59%),followed by therapeutic studies conducted in animals (19.32%).Japan approved DR studies in a similar ratio,with mechanistic studies accounting for 57.42% of all DR-related grants,followed by clinical interventional studies(15.23%) and therapeutic studies in animals (10.94%).In European countries,mechanistic DR studies still accounted for the largest proportion of all DR-related grants (37.50%),followed by clinical diagnostic studies (28.50%) and clinical observational studies (12.50%).Of note,the ratio of clinical studies was higher for DME-related grants than that for DRrelated grants (77.5 basic studiesversus81 clinical studies for NIH-approved DME grants;32 basic studies versus 21.5 clinical studies for DME grants approved by the other six countries).Mechanistic studies and clinical interventional studies accounted for more than half of the total DME-related grants(Figure 2B).

    Figure 2 |Proportion of research grants for basic (mechanistic study,non-clinical therapeutic study,novel animal model study,and non-clinical bioengineering study) and clinical (epidemiological study,clinical diagnostic study,observational study,and interventional study) studies addressing (A) diabetic retinopathy (DR) and (B) diabetic macular edema (DME) funded by the governments of global representative countries,and trends in funding,from 2012 to 2021.

    DR and clinical observational studies account for the majority of journal papers addressing DED

    We analyzed 4697 DED journal papers published between 2012 and 2021 retrieved from the Web of Science and PubMed databases.The number of published papers addressing DED increased steadily from 2012 (241 papers)to 2021 (843 papers),reflecting a growing interest in DED research globally.DR was the most commonly studied disease,accounting for 3342 papers (71.15%),followed by DME(1058;22.52%),DC (169;3.60%),and DG (128;2.73%;Figure 3A).Of these 4697 DED journal papers,3746 were research articles (79.75%),and 951 were review articles (20.25%).DR accounted was the main topic of 2629.5 research articles(70.20% of all research articles),followed by 908.5 DME research articles (24.25%),159 DC research articles (4.24%),and 49 DG research articles (1.31%).The ratio of disease topics addressed in review articles was similar,while the ratio of reviews that addressed DG was higher than that of research articles that focused on DG (8.31%vs.1.31%).Analyzing DED research article type showed that the number of clinical research papers far exceeded the number of basic research papers (2693vs.783 papers).Although DR was the major topic of both basic and clinical research papers,DME was the focus of more clinical papers than basic papers (892vs.17.5;30.10%vs.2.23%;Figure 3B).The majority of DR,DME,and DG research articles were clinical observational studies,whereas therapeutic studies in animals accounted for nearly half of the DC research papers (Figure 3C).

    Figure 3 |Research trends of 4697 journal papers reporting on four types of diabetic eye disease (DED),namely diabetic retinopathy (DR),diabetic macular edema (DME),diabetic cataracts (DC),and diabetic glaucoma (DG),listed in the Web of Science and PubMed databases (2012–2021).

    The United States dominates research output related to DED

    From 2012 to 2021,China and the United States published 19.55% and 17.53% of global DED journal papers,respectively.Other countries (the United Kingdom,India,Japan,Korea,Italy,and Australia) published only 3.41% to 5.95%.DR remained the dominant paper topic for all countries except Italy (Figure 4A).From 2012 to 2021,published DED journal papers from the United States received 22.58% of the citations to all DED papers published globally,far exceeding China(11.55%),the United Kingdom (7.95%),Singapore (5.57%),Italy (5.47%),and Australia (5.23%).Other countries received less than 5% of citations (Figure 4B).Papers published from the Netherlands had the highest average citation frequency(110.76 per paper),followed by South Africa (102.88),Thailand (96.81),Singapore (70.60),Denmark (62.92),Norway (57.83),and Germany (57.18) (Figure 4C).The top 10 countries and the average citation frequency per paper for each DED are listed inTable 1.The Netherlands (135.09),Norway (277.00),Switzerland (44.00),and Mexico (865.00)had the highest average citation frequencies per paper for DR,DME,DC,and DG,respectively.Next,we calculated RCI values to determine the relative position of a country’s papers in a certain discipline worldwide.Nineteen countries had RCI values >1.DED papers from the Netherlands had the highest RCI value (3.61),followed by Ethiopia,South Africa,Thailand,Singapore,Grenada,and Denmark (Figure 4D).

    Table 1 |Top 10 countries of average citation frequency per paper of each diabetic eye disease [diabetic retinopathy (DR),diabetic macular edema (DME),diabeticcataract (DC),and diabetic glaucoma (DG)] papers from 2012–2021

    Figure 4 |Published journal papers addressing four types of diabetic eye diseases (DED),namely diabetic retinopathy (DR),diabetic macular edema (DME),diabetic cataracts (DC),and diabetic glaucoma (DG),listed in the Web of Science and PubMed databases.Research output of the top 20 countries,encompassing publication counts,proportion of papers addressing the different disease types,total citation counts,average citations per paper,and relative citation impact (RCI)(2012–2021).

    The United States and the United Kingdom lead international collaborations in DED research

    International collaboration plays an important role in development of science and technology.Thus,we quantitatively analyzed papers about DED generated by international cooperation in major countries based on bibliometric and cooperation network analyses.The United States and the United Kingdom were at the center of the international cooperation network constructed for all DED papers published from 2012 to 2021 and exhibited close collaborations with China,Germany,Australia,and India.Many other countries,including Singapore,Portugal,Canada,Brazil,France,South Africa,Spain,Italy,Saudi Arabia,Israel,and New Zealand,also closely participated in international DED research collaboration.The United States and the United Kingdom were also the leading countries in international collaboration in DR,DC,and DG research.For DME publications,the United States and Germany exhibited close collaborative relationships with Australia,India,France,Italy,and Spain (Figure 5).We also observed changes in the relative overall centrality ranking of each country overtime.As shown inTable 2andAdditional Table 1,compared with 2012,in 2021 the United Kingdom replaced the United States as the world’s top country in DED research.India and Australia maintained their rankings as third and fourth globally,respectively,while China rose from sixth to fifth place.Singapore’s ranking dropped significantly from fifth to ninth in the world during the same time period.

    Table 2 |Degree and centrality of Top 25 countries in the international cooperation network in the field of diabetes eye disease in 2012 and 2021

    Figure 5 |International collaboration networks in the field of diabetic eye disease (DED) and its four disease types,namely diabetic retinopathy (DR),diabetic macular edema (DME),diabetic cataracts (DC),and diabetic glaucoma (DG),from 2012 to 2021 (based on all published papers listed in the Web of Science and PubMed database).

    DME is the major topic of clinical trials investigating DED

    The ultimate goal of drug and therapy development is to bring a novel compound or method with proven therapeutic efficacy to market.To analyze new drug and treatment development trends for DED,we identified all DED-related clinical trials registered between 2012 and 2021.A total of 415 clinical trials were conducted during this period,comprising 165 trials for DR (39.76%),241.5 trials for DME (58.19%),5.5 trials for dry eye disease (1.33%),and three trials for dysthyroid eye (DG) (0.72%).The number of annual studies did not change significantly from 2012 to 2021,ranging from 34 to 56 trials per year (Figure 6A).The US registered 157 trials during this time period,followed by China (51),Egypt (21),Switzerland (19),and Canada (14).North American (178),Asian (108),and European (87) countries conducted most of the DED clinical trials (Figure 6B).Of note,a large majority of those trials were either in phase 2 (104 trials;25.06%)or phase 4 (91 trials;21.93%).We observed only a slightly increasing trend in the number of phase 3 trials during this period,in terms of annual trial number (Figure 6C).Next, we assessed the mechanisms of the new drugs tested in the identified clinical trials.Angiogenesis inhibitors accounted for the vast majority,including 85 trials in total,while 65 trials tested VEGF inhibitors.Other drug categories included antiinflammatory drugs (41 trials),metabolic regulators (16 trials),neuroprotective drugs (11 trials),IOP-lowering drugs (nine trials),antioxidant drugs (seven trials),and anti-infectious drugs (four trials).Unfortunately,many of the above drugs were not new drugs,having already been approved by the FDA,and only a small number of newly developed drugs were tested (62 out of 182;34.07%;Figure 6D).

    Figure 6 |Clinical trials of treatments for various types of diabetic eye disease (DED) diseases,including diabetic retinopathy (DR),diabetic macular edema (DME),diabetic cataracts (DC),and diabetic glaucoma (DG) (2012–2021).These data show the distribution and temporal trends of these diseases within clinical trials,ranked trials by country and continent,proportions of clinical trial phases,and drug statistics.

    Few ophthalmic and DED drugs were newly approved for use

    Increased DED diagnosis and disease burden have led to an increased need for novel ophthalmic disease treatments.From 2012 to 2021,the US FDA approved 353 new drugs,of which only five were for ophthalmic diseases (1.42% of all new drugs).During the same period (2012–2021),the National Medical Products Administration (NMPA,China),Pharmaceuticals and Medical Devices Agency (PMDA,Japan),and European Medicines Agency (EMA,European Union) approved 5,15,and 15 new drugs for eye diseases,accounting for 3.45%,2.49%,and 2.06% of each agency’s total drug approvals during the period,respectively (Figure 7A).Of the 40 new ophthalmic drugs approved by the above agencies during this time period,nearly half were for treating glaucoma/ocular hypertension (17 drugs;42.50%),followed by macular diseases (five drugs;12.50%).Of particular note,the EMA approved three new drugs (Eylea,Duloxetine Mylan,and Byooviz) for treating diabetic eye damage (Figure 7B).

    Figure 7 |Comparison of new drug approvals by the Food and Drug Administration (FDA),National Medical Products Administration (NMPA),Pharmaceuticals and Medical Devices Agency (PMDA),and European Medicines Agency (EMA).

    Discussion

    Our study provides a comprehensive and up-to-date evaluation of global DED research trends.It is the largest bibliometric analysis of DED research to date,encompassing the full course of the scientific research process from research funding to paper publication,clinical trial,and new drug approval.Our findings indicate that DR remained the primary area of interest for global scientists and clinicians in the preclinical stages,including research grants and journal publications,between 2012 and 2021 (Gardner and Chew,2016).The United States led the world in terms of research investment and publication output regarding DED during this time period,while China made significant progress in both grant funding and research output,becoming the secondlargest DED research funder globally,producing the highest number of published papers about DED,and garnering the second-largest number of paper citations in the world over the past decade.In addition,DME emerged as the main focus area of focus for DED clinical trials over the past decade.Although 53.01% of the 415 trials that were registered from 2012 to 2021 were successfully completed,only 7.50% (3 out of 40) of the new drugs that were tested were approved for the treatment of diabetic eye damage.

    Currently,DR is the most common complication of diabetes(Oshitari,2022;Tang et al.,2023a).Its molecular pathogenesis is still not fully understood,and its treatment is challenging.Although VEGF inhibitors and other angiogenesis inhibitors have been used for decades to treat patients with DR,and demonstrate remarkable clinical benefits for many patients,a large number of patients still do not achieve clinically significant visual improvement (Wang and Lo,2018).Therefore,a deeper understanding of the pathophysiological processes underlying DR progression is needed to identify novel drug targets.This explains why more than half of the DR research grants funded over the past decade have been for mechanistic studies.To inhibit or reverse the progression of DR,not only in ophthalmological diseases,a large number of the grants and journal articles identified in out study focused on adipose tissue regulation,lipid/glucose re-balance,and organ crosstalk.Moreover,16 clinical trials tested the application of metabolic regulators (e.g.metformin,empagliflozin,and pemafibrate),which target systemic lipid/glucose metabolism.Although the number and funding amount of research grants from the major representative countries remained largely unchanged in the past decade,the number of global research papers on DED has drastically increased,by approximately 3.5 times,from 241 in 2012 to 843 in 2021.DED has gradually become a key focus of ophthalmology research.There are several possible explanations for this trend: (1) researchers and clinicians receiving good funding (e.g.company or other government funding types) to support their studies (Suresh,2012;Woelbert et al.,2021);(2) more efficient use of research funds;and (3) lack of high-impact papers in this field.Although DR was still the major disease type addressed in DED research articles,in contrast to research grants,the article topics shifted from mechanistic studies to clinical observational and interventional studies,implying that researchers are focusing more on translational research and clinical applications for DED-related diseases.

    DME is mainly caused by destruction of the blood-retinal barrier (BRB) in the macular region,increased permeability of capillaries and microangiomas,and accumulation of extracellular fluid.DME can occur at any stage of DR,and is an important factor leading to visual impairment in patients with DR (Wong et al.,2016).The number of adults worldwide with clinically significant macular edema is predicted to rise to 28.61 million in 2045.Thus,early disease stages urgently need to be addressed,both in terms of public awareness and in the development of new treatments to supplement the currently available VEGF inhibitor therapy and laser photocoagulation(Teo et al.,2021).Unlike for research grants and published papers,DME was the major topic of clinical trials for DED from 2012 to 2021.This might be the result of a combination of factors.Compared with DR,DC,and DG,(1) the pathogenesis of DME is relatively clear (BRB damage);(2) DME symptoms are relatively distinctive (3) DME treatment efficacy is easy to observe (e.g.OCT and fundus photography);and (4) DME has a significant impact on patient vision (Das et al.,2015;Chakravarthy et al.,2018;Jampol et al.,2020).Of note,many drugs tested in these clinical trials were already on the market,with approval for indications other than DED (120 out of 182;65.93%).Therefore,increasing investment in basic and translational research is urgently needed in order to discover novel therapeutic targets and develop more new drugs for DED.

    The global market for ophthalmic disease therapeutics is projected to grow from 35.57 billion USD in 2023 to 54.87 billion USD by 2030,for an overall annual growth rate of 6.40% during the forecast period (Insights,2023).However,we found that only three out of 40 new drugs (7.50%)approved by the FDA/NMPA/PMDA/EMA from 2012 to 2021 were for DR or other diabetic eye complications.Because retinal diseases have dominated the market in the past years,and the DR/DME patient population is growing,companies are investing more resources in new drug development,particularly VEGF inhibitors.For example,Genetech Inc.received FDA and EMA approval for faricimab for DME treatment in January and September 2022,respectively(Shirley,2022).Several new drugs currently in clinical trials are promising for DED treatment.One such drug is a novel αvβ3 inhibitor called OTT-166.This drug has completed a phase 1/2 randomized controlled trial (RCT) for the treatment of DME (NCT02914613).Additionally,a phase 2 RCT is currently underway to assess the safety and efficacy of OTT-166 for treating DR (NCT05409235).Another potential treatment for DR is eye drops containing somatostatin,which is a corticotropin-releasing hormone/growth hormone-releasing hormone inhibitor.A phase 3 clinical trial of this drug for the treatment of DR has been completed (NCT01726075).In subjects with proliferative DR,the administration of oral emixustat hydrochloride (a retinoid isomerohydrolase inhibitor) significantly improved central subfield thickness and total macular volume compared with the control group in a phase 2 RCT study (NCT02753400).Overall,these new drugs offer hope for the future treatment of DED and DR,and ongoing clinical trials will provide further insight into their effectiveness and safety.Aldose reductase inhibitors and antioxidants have been reported to alleviate DC and DG phenotypes in animal models (Pollreisz and Schmidt-Erfurth,2010;Snow et al.,2015;Himori et al.,2021);however,further preclinical studies and clinical trials are needed to demonstrate their suitability for clinical application.In terms of DR diagnosis,the FDA has recently approved a revolutionary EyeArt artificial intelligence system.This system is equipped with multiple cameras and is capable of autonomously detecting DR.The approval of this system is a significant development because it provides primary care clinics with an additional screening option for diabetic populations.

    This study had some limitations.Given the retrospective nature of our study,we deliberately chose a specific time frame for analysis to focus our investigation.While this approach allowed us to examine a relevant and significant period,it inherently limited the breadth of our scope.Consequently,our findings may not provide a fully exhaustive representation of all DED research.The emphasis on highly cited papers could potentially lead to misunderstandings regarding influential research,overlooking emerging studies with promising insights that have yet to accumulate substantial citations.When discussing new drug development,our focus on traditional small-molecule drugs might not sufficiently encompass the contemporary pharmaceutical landscape,which is increasingly influenced by biologics and gene therapy approaches.Moreover,in the era of globalization,international collaboration has become pivotal for countries to foster scientific and technological advancements.While an increasing number of influential papers rely on successful international collaborations,it cannot be assumed that such collaborative papers are of higher research caliber than those originating from a single country.To thoroughly investigate this,it is imperative to conduct independent analyses observing the impact of papers resulting from collaborations between various nations.

    Future studies could use enhanced data collection and analysis methods to encompass a broader range of sources and regions,thereby ensuring a more comprehensive representation of the global research landscape.Recognizing the intricate interplay between data,collaboration,funding,and research methodologies is essential to advancing our understanding of this field.

    In conclusion,although the number of patients with diabetes and DED is rapidly increasing worldwide,the basic and translational research related to DED over the past decade has been somewhat lacking,with limited treatment methods explored and only a few new drugs approved.Because of the growing demand for DED research,the global scientific community needs to make a substantial commitment to basic and clinical research into DED,particularly DC and DG,through active academic investigation,global collaboration,and novel drug development.

    Author contributions:ST and JX designed the study.YY,SJ,and JX collected all required data.YY,SJ,YS,ZC,LX,analyzed the data.YY,ST,and JX wrote and revised the manuscript.All authors approved the final version.ST and JX are the guarantors of this work and,as such,had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

    Conflicts of interest:No potential conflicts of interest relevant to this study were reported.

    Data availability statement:All relevant data are within the paper and its Additional files.

    Open access statement:This is an open access journal,and articles are distributed under the terms of the Creative Commons AttributionNonCommercial-ShareAlike 4.0 License,which allows others to remix,tweak,and build upon the work non-commercially,as long as appropriate credit is given and the new creations are licensed under the identical terms.

    Additional file:

    Additional Table 1:Papers from the top 5 countries with the highest average citation frequencies among the top 10 countries for each diabetic eye condition from 2012 to 2021.

    黄色配什么色好看| 婷婷成人精品国产| 国产精品不卡视频一区二区| 亚洲欧美一区二区三区黑人 | 久久青草综合色| 侵犯人妻中文字幕一二三四区| 老熟女久久久| 成人亚洲精品一区在线观看| 亚洲欧洲国产日韩| 日本av手机在线免费观看| 久久精品夜色国产| 成年动漫av网址| 狠狠婷婷综合久久久久久88av| 观看av在线不卡| 制服人妻中文乱码| 国产69精品久久久久777片| 一区二区日韩欧美中文字幕 | 国产毛片在线视频| 亚洲天堂av无毛| 两个人看的免费小视频| 韩国高清视频一区二区三区| 99re6热这里在线精品视频| 这个男人来自地球电影免费观看 | 极品人妻少妇av视频| 亚洲,一卡二卡三卡| 超碰97精品在线观看| 国产成人午夜福利电影在线观看| 国产免费一级a男人的天堂| 26uuu在线亚洲综合色| 一边亲一边摸免费视频| 欧美另类一区| 国产深夜福利视频在线观看| 丰满饥渴人妻一区二区三| 国产色婷婷99| 捣出白浆h1v1| 黄色一级大片看看| a级毛片在线看网站| 亚洲综合色惰| 国产精品免费大片| 成人漫画全彩无遮挡| 一本大道久久a久久精品| 免费看av在线观看网站| 国产日韩欧美亚洲二区| 日韩精品免费视频一区二区三区 | 少妇高潮的动态图| 国产成人精品久久久久久| 亚洲av中文av极速乱| 久久久久久人妻| 久久精品国产鲁丝片午夜精品| 久久久久久久亚洲中文字幕| 亚洲精华国产精华液的使用体验| 国产一区二区激情短视频| 国产一区二区激情短视频| 亚洲欧美一区二区三区黑人| 国产精品 国内视频| 亚洲熟女精品中文字幕| 免费在线观看日本一区| 国产精品影院久久| 亚洲av第一区精品v没综合| 成人国语在线视频| 中文字幕精品免费在线观看视频| 在线观看免费视频网站a站| 久久99一区二区三区| 成年女人毛片免费观看观看9 | 亚洲精品粉嫩美女一区| 免费不卡黄色视频| 超碰成人久久| 亚洲国产看品久久| 嫁个100分男人电影在线观看| 黄色丝袜av网址大全| 一级黄色大片毛片| 亚洲精品美女久久av网站| 国产欧美日韩一区二区精品| 亚洲欧美一区二区三区久久| 一a级毛片在线观看| 夜夜爽天天搞| 亚洲在线自拍视频| 丝瓜视频免费看黄片| 亚洲精品粉嫩美女一区| 狂野欧美激情性xxxx| 欧美国产精品va在线观看不卡| 亚洲第一av免费看| 两性夫妻黄色片| 亚洲在线自拍视频| videos熟女内射| 精品国产乱码久久久久久男人| 久久久国产成人精品二区 | 亚洲国产毛片av蜜桃av| 午夜福利在线观看吧| 亚洲精品国产色婷婷电影| 国产亚洲精品久久久久久毛片 | 91九色精品人成在线观看| 亚洲少妇的诱惑av| 午夜亚洲福利在线播放| 国产高清videossex| 亚洲中文字幕日韩| 国产一区二区三区在线臀色熟女 | 国产亚洲精品一区二区www | 美女福利国产在线| 午夜免费成人在线视频| 母亲3免费完整高清在线观看| 国产片内射在线| 国产亚洲一区二区精品| 国产午夜精品久久久久久| 99久久国产精品久久久| 下体分泌物呈黄色| 99在线人妻在线中文字幕 | 国产不卡一卡二| 久久久久久久久久久久大奶| 黑人欧美特级aaaaaa片| 男女午夜视频在线观看| 视频在线观看一区二区三区| 91精品国产国语对白视频| 99国产极品粉嫩在线观看| 丝袜美腿诱惑在线| 丰满迷人的少妇在线观看| 12—13女人毛片做爰片一| 五月开心婷婷网| 极品人妻少妇av视频| 两性午夜刺激爽爽歪歪视频在线观看 | 亚洲欧美色中文字幕在线| 交换朋友夫妻互换小说| 看免费av毛片| 国产精品香港三级国产av潘金莲| 男人操女人黄网站| 亚洲va日本ⅴa欧美va伊人久久| 精品人妻在线不人妻| 欧美亚洲 丝袜 人妻 在线| 看免费av毛片| 午夜福利欧美成人| 最近最新免费中文字幕在线| 美女福利国产在线| 巨乳人妻的诱惑在线观看| 久久精品成人免费网站| 91九色精品人成在线观看| av在线播放免费不卡| 久久精品成人免费网站| 欧美日韩国产mv在线观看视频| 国产又爽黄色视频| 亚洲精华国产精华精| 精品久久久久久久久久免费视频 | 天堂俺去俺来也www色官网| 国产91精品成人一区二区三区| 一级片免费观看大全| 欧美另类亚洲清纯唯美| 亚洲一区二区三区不卡视频| 下体分泌物呈黄色| av线在线观看网站| 国产不卡av网站在线观看| 天天添夜夜摸| 一区二区三区精品91| 老司机午夜十八禁免费视频| 国产在线精品亚洲第一网站| 国产成人免费无遮挡视频| 一二三四在线观看免费中文在| 人人妻,人人澡人人爽秒播| 国产精品二区激情视频| 亚洲五月天丁香| 精品少妇久久久久久888优播| 亚洲av成人不卡在线观看播放网| 欧美精品人与动牲交sv欧美| 色综合婷婷激情| 日韩 欧美 亚洲 中文字幕| 丝袜人妻中文字幕| av电影中文网址| 一区二区日韩欧美中文字幕| 日韩一卡2卡3卡4卡2021年| 欧美日韩av久久| 十八禁网站免费在线| 女人精品久久久久毛片| 亚洲欧美激情在线| 精品国产乱码久久久久久男人| 国产精品欧美亚洲77777| 亚洲精品在线美女| 精品国产乱码久久久久久男人| 丰满人妻熟妇乱又伦精品不卡| 久久婷婷成人综合色麻豆| 精品福利永久在线观看| 中文字幕高清在线视频| 成年动漫av网址| 麻豆国产av国片精品| 香蕉久久夜色| 99精品欧美一区二区三区四区| 精品无人区乱码1区二区| 一边摸一边抽搐一进一出视频| 欧美激情 高清一区二区三区| 午夜老司机福利片| 下体分泌物呈黄色| 老司机影院毛片| 国产成人啪精品午夜网站| 欧美 日韩 精品 国产| 免费观看人在逋| 正在播放国产对白刺激| www.自偷自拍.com| 男人的好看免费观看在线视频 | 伊人久久大香线蕉亚洲五| 男女免费视频国产| 一区二区三区国产精品乱码| 欧美午夜高清在线| 国产单亲对白刺激| 日韩免费av在线播放| 大型av网站在线播放| 精品一区二区三区av网在线观看| 精品一区二区三卡| 美女 人体艺术 gogo| 9热在线视频观看99| 捣出白浆h1v1| 欧美精品av麻豆av| 欧美精品高潮呻吟av久久| 亚洲专区国产一区二区| 91av网站免费观看| 久久 成人 亚洲| 亚洲精品久久成人aⅴ小说| 精品熟女少妇八av免费久了| 亚洲午夜精品一区,二区,三区| 亚洲精品美女久久av网站| 色综合欧美亚洲国产小说| 国产亚洲一区二区精品| 满18在线观看网站| 女人爽到高潮嗷嗷叫在线视频| 一进一出好大好爽视频| 成人三级做爰电影| 亚洲少妇的诱惑av| 日韩有码中文字幕| 亚洲熟女毛片儿| 99国产综合亚洲精品| 成人影院久久| 一区福利在线观看| 在线av久久热| 亚洲专区中文字幕在线| 成人手机av| 免费在线观看视频国产中文字幕亚洲| 国产一区二区三区综合在线观看| 在线播放国产精品三级| 男女午夜视频在线观看| 18禁黄网站禁片午夜丰满| 欧美日韩精品网址| 亚洲欧美一区二区三区黑人| 久久精品国产综合久久久| 欧美激情 高清一区二区三区| 欧美黄色淫秽网站| 亚洲全国av大片| 午夜福利在线观看吧| 搡老熟女国产l中国老女人| a级片在线免费高清观看视频| 女人精品久久久久毛片| 丝袜在线中文字幕| 十八禁人妻一区二区| 老司机深夜福利视频在线观看| 99国产精品免费福利视频| 欧美一级毛片孕妇| av天堂在线播放| 一区二区三区精品91| 亚洲va日本ⅴa欧美va伊人久久| 久久久水蜜桃国产精品网| 免费久久久久久久精品成人欧美视频| 国产精品影院久久| 99热国产这里只有精品6| 亚洲专区国产一区二区| 大型av网站在线播放| 色综合婷婷激情| 美女高潮喷水抽搐中文字幕| 黄色丝袜av网址大全| 天天躁狠狠躁夜夜躁狠狠躁| 色综合欧美亚洲国产小说| 国产精品久久久久久精品古装| 69av精品久久久久久| 成人精品一区二区免费| 国产午夜精品久久久久久| av一本久久久久| 国产一区有黄有色的免费视频| 久久精品91无色码中文字幕| 老司机亚洲免费影院| 国产免费现黄频在线看| 亚洲精品久久午夜乱码| 国产av一区二区精品久久| 亚洲成a人片在线一区二区| 黄色 视频免费看| 久久亚洲真实| 老司机亚洲免费影院| 90打野战视频偷拍视频| 中文字幕av电影在线播放| 丰满的人妻完整版| 夫妻午夜视频| 美女午夜性视频免费| 热99re8久久精品国产| 亚洲三区欧美一区| 精品福利永久在线观看| 亚洲一区中文字幕在线| 亚洲七黄色美女视频| 一区二区三区国产精品乱码| 大香蕉久久网| 亚洲 欧美一区二区三区| 国产精品国产av在线观看| 成年女人毛片免费观看观看9 | 欧美日韩成人在线一区二区| av免费在线观看网站| 国产伦人伦偷精品视频| 精品久久久精品久久久| 国产欧美日韩精品亚洲av| 色尼玛亚洲综合影院| 搡老岳熟女国产| aaaaa片日本免费| 悠悠久久av| 麻豆av在线久日| 欧美人与性动交α欧美软件| 中文字幕人妻丝袜制服| 高清欧美精品videossex| 欧美激情极品国产一区二区三区| 国产99久久九九免费精品| 国产欧美日韩一区二区三| 欧美另类亚洲清纯唯美| 一a级毛片在线观看| 首页视频小说图片口味搜索| 免费看a级黄色片| 国产精品美女特级片免费视频播放器 | av网站在线播放免费| 人人妻,人人澡人人爽秒播| 99香蕉大伊视频| 黄网站色视频无遮挡免费观看| 交换朋友夫妻互换小说| 亚洲自偷自拍图片 自拍| 久久久久久久午夜电影 | 亚洲三区欧美一区| 久久精品成人免费网站| 麻豆乱淫一区二区| 成人免费观看视频高清| 亚洲色图综合在线观看| 亚洲精品粉嫩美女一区| 久久 成人 亚洲| 亚洲精品美女久久av网站| 精品第一国产精品| 少妇被粗大的猛进出69影院| 大片电影免费在线观看免费| 日韩 欧美 亚洲 中文字幕| 欧美丝袜亚洲另类 | 亚洲欧美精品综合一区二区三区| 夜夜爽天天搞| 国产精品免费视频内射| 一边摸一边抽搐一进一小说 | 成人黄色视频免费在线看| 成人特级黄色片久久久久久久| 久久精品成人免费网站| 亚洲熟女毛片儿| 国产黄色免费在线视频| 老熟妇乱子伦视频在线观看| 欧美在线一区亚洲| 9热在线视频观看99| 亚洲一码二码三码区别大吗| 精品久久久精品久久久| 少妇裸体淫交视频免费看高清 | 成年版毛片免费区| 中亚洲国语对白在线视频| 下体分泌物呈黄色| 免费看十八禁软件| 国产视频一区二区在线看| 99国产精品一区二区蜜桃av | 亚洲五月婷婷丁香| 妹子高潮喷水视频| 中文字幕人妻熟女乱码| www.自偷自拍.com| 国产亚洲欧美98| 午夜免费成人在线视频| 女人被狂操c到高潮| 亚洲少妇的诱惑av| 亚洲第一欧美日韩一区二区三区| 一a级毛片在线观看| 大片电影免费在线观看免费| 精品国产一区二区三区四区第35| √禁漫天堂资源中文www| 精品一区二区三卡| 丰满人妻熟妇乱又伦精品不卡| 人妻 亚洲 视频| 欧美中文综合在线视频| 国产欧美日韩一区二区三| 欧美精品av麻豆av| 亚洲久久久国产精品| 高潮久久久久久久久久久不卡| 国产精品免费一区二区三区在线 | 国产xxxxx性猛交| 少妇的丰满在线观看| 精品亚洲成a人片在线观看| 性少妇av在线| 天天影视国产精品| 国产精品 欧美亚洲| 国产主播在线观看一区二区| www.熟女人妻精品国产| 深夜精品福利| 国产成人免费无遮挡视频| 欧美日韩中文字幕国产精品一区二区三区 | 午夜福利,免费看| 国产在线精品亚洲第一网站| 黄色视频不卡| 亚洲欧美一区二区三区久久| 久久精品国产亚洲av高清一级| 欧美激情久久久久久爽电影 | 欧美日韩亚洲综合一区二区三区_| 欧美乱码精品一区二区三区| 天堂中文最新版在线下载| 两性午夜刺激爽爽歪歪视频在线观看 | 亚洲一码二码三码区别大吗| 在线观看66精品国产| 99riav亚洲国产免费| 精品国产超薄肉色丝袜足j| 后天国语完整版免费观看| 亚洲国产欧美日韩在线播放| 三级毛片av免费| 日韩欧美国产一区二区入口| 可以免费在线观看a视频的电影网站| 久久国产精品男人的天堂亚洲| 国产男女内射视频| 1024香蕉在线观看| 国产激情欧美一区二区| 国产一区二区三区在线臀色熟女 | 久久国产乱子伦精品免费另类| 欧美丝袜亚洲另类 | 好男人电影高清在线观看| 久久这里只有精品19| av中文乱码字幕在线| 久久久久视频综合| 一区福利在线观看| 制服人妻中文乱码| 国产精品九九99| 王馨瑶露胸无遮挡在线观看| 精品免费久久久久久久清纯 | 国产熟女午夜一区二区三区| 婷婷精品国产亚洲av在线 | 亚洲第一青青草原| 国精品久久久久久国模美| 日韩熟女老妇一区二区性免费视频| 色综合婷婷激情| 免费观看人在逋| 欧美不卡视频在线免费观看 | 91大片在线观看| 99re6热这里在线精品视频| 啦啦啦视频在线资源免费观看| 成在线人永久免费视频| 欧美日韩瑟瑟在线播放| 亚洲人成电影观看| 亚洲 国产 在线| 欧美丝袜亚洲另类 | 人人妻,人人澡人人爽秒播| 久久精品国产99精品国产亚洲性色 | 国产片内射在线| 男女床上黄色一级片免费看| 亚洲av成人一区二区三| 满18在线观看网站| 丰满饥渴人妻一区二区三| 在线观看免费午夜福利视频| 国产亚洲精品第一综合不卡| 性少妇av在线| 精品久久久久久,| 国产激情久久老熟女| av视频免费观看在线观看| 国产亚洲欧美精品永久| 一级a爱片免费观看的视频| 成人国语在线视频| av天堂久久9| 亚洲国产精品合色在线| 亚洲熟妇熟女久久| 色尼玛亚洲综合影院| 免费少妇av软件| 国产精品成人在线| 变态另类成人亚洲欧美熟女 | 日日爽夜夜爽网站| 久久久久久久午夜电影 | 黄片播放在线免费| 美女高潮喷水抽搐中文字幕| 高清av免费在线| 天天躁狠狠躁夜夜躁狠狠躁| 精品一区二区三区四区五区乱码| 麻豆乱淫一区二区| 久久午夜亚洲精品久久| 亚洲专区中文字幕在线| 麻豆国产av国片精品| 午夜免费成人在线视频| 国产区一区二久久| 天天躁狠狠躁夜夜躁狠狠躁| 老司机福利观看| 欧美黑人精品巨大| 亚洲精品国产色婷婷电影| 80岁老熟妇乱子伦牲交| 免费久久久久久久精品成人欧美视频| 午夜福利视频在线观看免费| 欧美丝袜亚洲另类 | 91av网站免费观看| 欧美 亚洲 国产 日韩一| 亚洲国产精品一区二区三区在线| 亚洲国产精品合色在线| 老鸭窝网址在线观看| 久久国产精品影院| 高清毛片免费观看视频网站 | 又黄又爽又免费观看的视频| 久久精品国产亚洲av高清一级| av不卡在线播放| 国产精品久久久久久人妻精品电影| 久久国产精品影院| 制服诱惑二区| 亚洲专区中文字幕在线| e午夜精品久久久久久久| 国产xxxxx性猛交| 欧美国产精品一级二级三级| 国产免费av片在线观看野外av| 两个人看的免费小视频| 欧美日本中文国产一区发布| 亚洲av成人一区二区三| 国产精品av久久久久免费| 久久青草综合色| 天堂√8在线中文| 看片在线看免费视频| 亚洲性夜色夜夜综合| 国产在视频线精品| 午夜福利免费观看在线| 男男h啪啪无遮挡| 久久精品人人爽人人爽视色| 免费观看精品视频网站| 天堂√8在线中文| 国产激情欧美一区二区| 国产午夜精品久久久久久| 久久国产亚洲av麻豆专区| 国产亚洲欧美在线一区二区| 美女福利国产在线| 亚洲人成77777在线视频| 国产成人精品久久二区二区免费| 久久精品人人爽人人爽视色| 丝袜美足系列| 天天添夜夜摸| 日韩免费高清中文字幕av| 久久人妻福利社区极品人妻图片| 又黄又粗又硬又大视频| 狠狠婷婷综合久久久久久88av| 中文字幕精品免费在线观看视频| 天堂中文最新版在线下载| 亚洲午夜精品一区,二区,三区| 国产精品 国内视频| 国产精品亚洲一级av第二区| 18在线观看网站| 国产成人欧美| 国产欧美日韩综合在线一区二区| av线在线观看网站| 亚洲一区高清亚洲精品| 日本欧美视频一区| 国产激情久久老熟女| 少妇被粗大的猛进出69影院| 大陆偷拍与自拍| 成年女人毛片免费观看观看9 | 午夜福利乱码中文字幕| 99久久综合精品五月天人人| 18禁观看日本| 国产极品粉嫩免费观看在线| 纯流量卡能插随身wifi吗| 午夜老司机福利片| 国产野战对白在线观看| 18禁裸乳无遮挡动漫免费视频| 啦啦啦免费观看视频1| 高清av免费在线| 国产一卡二卡三卡精品| 怎么达到女性高潮| 久久精品人人爽人人爽视色| 好看av亚洲va欧美ⅴa在| 日韩欧美免费精品| 老熟妇乱子伦视频在线观看| 这个男人来自地球电影免费观看| 国产一区二区三区视频了| 无人区码免费观看不卡| 色在线成人网| 国产激情久久老熟女| 亚洲,欧美精品.| 国产成人免费无遮挡视频| 极品教师在线免费播放| 免费日韩欧美在线观看| 1024视频免费在线观看| 国产亚洲一区二区精品| 操出白浆在线播放| 午夜影院日韩av| 91麻豆av在线| 欧美老熟妇乱子伦牲交| 国产99久久九九免费精品| 午夜福利在线免费观看网站| 99国产精品一区二区三区| 制服诱惑二区| 在线观看免费视频网站a站| 午夜日韩欧美国产| 91国产中文字幕| 午夜福利欧美成人| 亚洲av片天天在线观看| 久久精品亚洲av国产电影网| 啦啦啦免费观看视频1| 99国产精品99久久久久| 亚洲一区二区三区欧美精品| 波多野结衣av一区二区av| 精品国产乱子伦一区二区三区| 亚洲一码二码三码区别大吗| 日韩制服丝袜自拍偷拍| av天堂久久9| 亚洲av日韩在线播放| 黑人巨大精品欧美一区二区蜜桃| 久久国产精品人妻蜜桃| 亚洲av熟女| 亚洲伊人色综图| 午夜免费鲁丝| 久久久久久久久久久久大奶| 国产亚洲精品第一综合不卡| 亚洲 欧美一区二区三区| 亚洲精品自拍成人| 国产成人系列免费观看| 久久 成人 亚洲| 高清毛片免费观看视频网站 | 日韩欧美三级三区| 亚洲一区中文字幕在线| 日本vs欧美在线观看视频| 亚洲av成人av| 一级黄色大片毛片| 老司机午夜福利在线观看视频| 国产免费现黄频在线看|